This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13 L4 3 L3

=> d abs fhitstr bib 1-3

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2010 ACS on STN GI

I

AB The present invention provides amorphous solid forms of the compd. of formula (I), (R)-4a-ethoxymethyl-1-(4-fluorophenyl)-6-(4-trifluoromethylbenzenesulfonyl)-4,4a,5,6,7,8-hexahydro-1H, 1,2,6-triazacyclopenta[b]naphthalene, as well as methods for preparing the compound of formula I by precipitation

IT 1018679-79-2

RL: PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (solid amorphous forms and process for preparing)

RN 1018679-79-2 CAPLUS

CN 1H-Pyrazolo[3,4-g]isoquinoline, 4a-(ethoxymethyl)-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-6-[[4-(trifluoromethyl)phenyl]sulfonyl]-, (4aR)-(CA INDEX NAME)

Absolute stereochemistry.

AN 2010:1435796 CAPLUS Full-text

DN 153:627108

TI Solid amorphous forms and process for preparing

IN Clark, Robin; Fry, Doug

PA Corcept Therapeutics, Inc., USA

```
SO
     PCT Int. Appl., 18pp.
     CODEN: PIXXD2
```

DTPatent

LA English

FAN.		1 TENT	NO.			KIN	D	DATE			APPL	ICAT	ION 1	NO.		D	ATE		
ΡI	WO 2010132445			A1 20101118			•	WO 2010-US34382					20100511						
		W:	ΑE,	AG,	AL,	AM,	AO,	ΑT,	ΑU,	AZ,	BA,	BB,	BG,	BH,	BR,	BW,	BY,	BZ,	
			CA,	CH,	CL,	CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DO,	DZ,	EC,	EE,	EG,	
			ES,	FI,	GB,	GD,	GE,	GH,	GM,	GT,	HN,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	
			ΚE,	KG,	KM,	KN,	KP,	KR,	KΖ,	LA,	LC,	LK,	LR,	LS,	LT,	LU,	LY,	MA,	
			MD,	ME,	MG,	MK,	MN,	MW,	MX,	MY,	MZ,	NA,	NG,	NI,	NO,	NZ,	OM,	PE,	
			PG,	PH,	PL,	PT,	RO,	RS,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SM,	ST,	SV,	
			SY,	TH,	ТJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	ZA,	ZM,	ZW
		RW:	AL,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HR,	
			HU,	ΙE,	IS,	IT,	LT,	LU,	LV,	MC,	MK,	MT,	NL,	NO,	PL,	PT,	RO,	SE,	
			SI,	SK,	SM,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	
			ΝE,	SN,	TD,	ΤG,	BW,	GH,	GM,	ΚE,	LR,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	
			TZ,	UG,	ZM,	ZW,	ΑM,	ΑZ,	BY,	KG,	KΖ,	MD,	RU,	ΤJ,	TM				
US 20100292477 A1 20101118 US 2010-777340 20100511																			
PRAI US 2009-177483P P 20090512																			
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT																			

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT 3 ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 2 OF 3 CAPLUS COPYRIGHT 2010 ACS on STN L4

AΒ Addn. of the 4-fluorophenylpyrazole group to the previously described 2azadecalin glucocorticoid receptor (GR) antagonist 1 resulted in significantly enhanced functional activity. SAR of the bridgehead substituent indicated that whereas groups as small as Me afforded high GR binding, GR functional activity was enhanced by larger groups such as benzyl, substituted ethers, and aminoalkyl derivs. GR antagonists with binding and functional activity comparable to mifepristone were discovered (e.g., 52: GR binding Ki 0.7 nM; GR reporter gene functional Ki 0.6 nM) and found to be highly selective over other steroid receptors. Analogs 43 and 45 had >50% oral bioavailability in the dog.

864972-02-1P ΙT

> RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(1H-pyrazolo[3,4-q]hexahydro-isoquinolines as selective glucocorticoid receptor antagonists)

RN 864972-02-1 CAPLUS

1H-Pyrazolo[3,4-g] isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl] sulfonyl]-CN 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-methyl-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.

AN 2008:232071 CAPLUS Full-text

DN 148:440269

TI 1H-Pyrazolo[3,4-g]hexahydro-isoquinolines as selective glucocorticoid receptor antagonists with high functional activity

AU Clark, Robin D.; Ray, Nicholas C.; Williams, Karen; Blaney, Paul; Ward, Stuart; Crackett, Peter H.; Hurley, Christopher; Dyke, Hazel J.; Clark, David E.; Lockey, Peter; Devos, Rene; Wong, Melanie; Porres, Soraya S.; Bright, Colin P.; Jenkins, Robert E.; Belanoff, Joseph

CS Corcept Therapeutics, Menlo Park, CA, 94025, USA

SO Bioorganic & Medicinal Chemistry Letters (2008), 18(4), 1312-1317 CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier Ltd.

DT Journal

LA English

OS CASREACT 148:440269

OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2010 ACS on STN GI

Title compds. I [L1 and L2 independently = a bond, O, S, etc.; A = (un)substituted 5-6 membered heterocycloalkyl or heteroaryl; R1 = H, (un)substituted alkyl, heteroalkyl, etc.; R2 = (un)substituted alkyl, heteroalkyl, cycloalkyl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as modulators of glucocorticoid receptor. Thus, II was prepared by cyclization of (S)-8a-benzyl-2-(4-tert-butyl-benzenesulfonyl)-7-[1-hydroxy-meth-(Z)-ylidene]-1,3,4,7,8,8a-hexahydro-2H-isoquinolin-6-one (preparation given) with hydrazine hydrate. The activity of I was evaluated in glucocorticoid receptor binding assay and it was revealed that selected compds. of the invention displayed IC50 values in the range of 10 up to 100 nm and others below 10 nM. Pharmaceutical compns. comprising I are disclosed.

II 864972-22-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of triazacyclopenta[b]naphthalene derivs. as modulators of glucocorticoid receptor)

RN 864972-22-5 CAPLUS

CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-carboxylic acid, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-, methyl ester, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.

AN 2005:1021750 CAPLUS Full-text

DN 143:306309

TI Preparation of triazacyclopenta[b]naphthalene derivatives as modulators of glucocorticoid receptor

IN Clark, Robin D.; Ray, Nicholas C.; Blaney, Paul M.; Hurley, Christopher
A.; Williams, Karen

PA Corcept Therapeutics, Inc., USA

SO PCT Int. Appl., 160 pp.

CODEN: PIXXD2

DT Patent

LA English FAN.CNT 1																			
						KIND DATE				APPLICATION NO.					DATE				
ΡI	WO	WO 2005087769				A1		20050922			WO 2005-US8049					20050309			
		W:						ΑU,					•						
								DE,											
								ID,											
					•			LV,					•						
					•		•	PL,				•	•					•	
		D	,	,	,	,	,	TT,	,	,	,	,	,	,	,	,	,	,	ΖW
		RW:						MW,											
								RU,											
								GR, BF,											
			,	•	,	TD,	,	Dr,	DU,	Cr,	CG,	$C_{\perp}$ ,	CM,	GA,	GN,	GQ,	GW,	М.,	
	ΔII	2005				•		2005	0922		AII 2	005-	2224	21		2	0050	309	
	AU 2005222421 AU 2005222421														200000				
		2558899									CA 2005-2558899					20050309			
						A1 20061227				EP 2005-725295									
	ΕP	1735308																	
		R:	AT,	BE,	ВG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	
			IS,	ΙT,	LI,	LT,	LU,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR			
	CN	:N 101027301				Α	A 20070829				CN 2005-80011481					20050309			
				Τ	T 20071011				JP 2007-503030					20050309					
	ΑT				_					AT 2005-725295					20050309				
										PT 2005-725295					20050309				
	_	S 2313317			T3 20090301														
		550362																	
		A 2006008306														20061005			
										KR 2006-7020988									
	ΙN	2006	СИ03	745		А		2007	0615		IN 2	006-	CN37	45		2	0061	009	

US 20070281928	A1	20071206 US 2007-591884	20070507						
HK 1104813	A1	20090403 HK 2007-106903	20070627						
	P	20040309							
WO 2005-US8049	W	20050309							
		AVAILABLE IN LSUS DISPLAY FO	RMAT						
OS CASREACT 143:306309;	MARPA	143:306309							
OSC.G 4 THERE ARE 4	CAPLU	RECORDS THAT CITE THIS RECOR	D (5 CITINGS)						
RE.CNT 2 THERE ARE 2	CITED	REFERENCES AVAILABLE FOR THIS	RECORD						
ALL CITATIONS AVAILABLE IN THE RE FORMAT									